Reckitt Benckiser Group stock (GB00B24CGK77): focus shifts to turnaround after weak 2024 sales

Reckitt Benckiser Group is navigating slower growth, a CEO change and legal headwinds while pushing a margin-focused turnaround. Recent annual results and guidance updates keep investors watching execution risk and cash generation.

Reckitt Benckiser Group has remained in the spotlight after reporting weaker-than-expected 2024 sales and outlining a turnaround plan focused on efficiency, brand investment and cash generation, according to the company’s full-year results release published in early 2025 and subsequent investor communications from the same period, as reported by Reckitt investor materials as of 02/26/2025 and coverage by Reuters as of 02/27/2025.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Reckitt Benckiser
• Sector/industry: Consumer health and hygiene products
• Headquarters/country: Slough, United Kingdom
• Core markets: Global presence with strong positions in Europe, North America and emerging markets
• Key revenue drivers: Branded consumer health, hygiene and nutrition products
• Home exchange/listing venue: London Stock Exchange (ticker: RKT)
• Trading currency: GBP

Reckitt Benckiser Group: core business model

Reckitt Benckiser Group operates a portfolio of consumer brands across health, hygiene and nutrition, including well-known names such as Dettol, Lysol, Durex, Nurofen and Enfamil. The company’s strategy centers on building category-leading brands in everyday-use product segments that benefit from recurring demand, which can provide a relatively resilient revenue base across economic cycles, according to Reckitt annual report 2024 as of 03/15/2025.

The business is organized around consumer health, hygiene and nutrition units, each with its own portfolio and innovation pipeline. In consumer health, the focus is on over-the-counter medicines, intimate wellness and self-care products, while hygiene includes disinfectants and household cleaners. Nutrition covers infant formula and specialty nutrition categories. This portfolio approach allows Reckitt to balance growth profiles and regulatory risks across different geographies, a point that has been highlighted in management presentations summarized by Reckitt investor materials as of 03/20/2025.

Reckitt’s business model relies on maintaining strong brand equity through marketing, consistent product quality and targeted innovation. The group invests a significant share of revenue into advertising and consumer insight work, aiming to secure premium shelf space and pricing power with retailers. At the same time, cost efficiency programs in manufacturing and procurement are designed to protect margins and fund these brand investments. This combination of scale, brand strength and cost discipline is central to how the company seeks to compete with global peers in the consumer packaged goods sector.

Another key feature of Reckitt’s model is its exposure to regulatory environments in health and nutrition. Products such as over-the-counter medicines and infant formula are subject to strict safety and labeling rules, which can create barriers to entry but also introduce compliance costs and potential legal risks. Management has emphasized the importance of product stewardship and quality systems in mitigating these risks, as described in risk disclosures in the 2024 annual report, according to Reckitt annual report 2024 as of 03/15/2025.

Main revenue and product drivers for Reckitt Benckiser Group

Revenue at Reckitt Benckiser Group is primarily driven by its health and hygiene brands, which account for a majority of group sales. Over-the-counter products such as Nurofen, Mucinex and Strepsils benefit from seasonal patterns but also from structural trends like aging populations and increased focus on self-care, according to the company’s commentary in its full-year 2024 results published in February 2025, as reported by Reckitt results centre as of 02/26/2025. Hygiene products, including Dettol and Lysol, saw a demand surge during the pandemic and have since normalized, but management continues to point to elevated consumer awareness around hygiene.

The nutrition division, anchored by the Enfamil brand, represents another significant revenue pillar. This segment has been under scrutiny following legal claims in the United States related to infant formula and premature infants, which management has disclosed as a contingent liability risk. While the company has stated that it intends to defend its position vigorously, the legal situation has contributed to investor uncertainty around the medium-term earnings trajectory in nutrition, according to coverage from Reuters as of 03/01/2025.

Geographically, North America and Europe are key revenue contributors, with the United States representing a particularly important market for health and hygiene products. The company has highlighted strong positions in categories such as disinfectants and cough and cold remedies in the US, which ties Reckitt’s performance closely to consumer spending and healthcare trends in one of the world’s largest consumer markets. Emerging markets in Asia and Latin America provide additional growth potential, although they often come with higher volatility and currency risk.

Pricing and mix are important drivers for Reckitt’s top line. Management has pushed through price increases in recent years to offset higher input costs, while also focusing on premium sub-brands and format innovations. This strategy has supported revenue even when volumes have been under pressure in some categories. However, the ability to continue raising prices depends on consumer acceptance and competitive dynamics, an issue noted in the company’s discussion of market conditions in its 2024 annual report, as summarized by Reckitt annual report 2024 as of 03/15/2025.

Industry trends and competitive position

Reckitt Benckiser Group operates in highly competitive global consumer health and hygiene markets, where multinational companies and strong regional players vie for shelf space and consumer loyalty. Industry trends such as increased health awareness, demand for hygiene products and a shift toward self-care support long-term consumption of many of Reckitt’s categories. At the same time, private-label offerings and digital-first brands challenge established players on price and innovation speed, as highlighted in sector analyses cited by Financial Times as of 04/05/2025.

The company’s competitive position benefits from its diversified brand portfolio and global distribution footprint. Its leading brands often hold strong market shares in core categories, allowing for economies of scale in marketing and supply chain operations. However, the firm faces intense competition from other global consumer goods companies in categories such as OTC pain relief, disinfectants and infant formula. Maintaining and growing market share requires sustained investment in advertising, product innovation and digital capabilities, particularly as more consumers shift to online purchasing and seek detailed product information before buying.

Another layer of competition comes from regulatory and reputational factors. Companies in health and nutrition can face significant scrutiny over product claims, safety and environmental impact. Reckitt has highlighted initiatives in sustainability, packaging reduction and responsible marketing to differentiate its brands and respond to consumer expectations, according to its sustainability disclosures from 2024 and 2025, as reported on the company’s website by Reckitt sustainability report 2024 as of 06/30/2025. How effectively these initiatives resonate with consumers and regulators could influence the company’s competitive standing in the coming years.

Why Reckitt Benckiser Group matters for US investors

Although Reckitt Benckiser Group is listed on the London Stock Exchange, its significant exposure to the United States makes it relevant for US-focused investors who track global consumer goods and health-related themes. The company derives a meaningful portion of its revenue from North America, particularly through its hygiene and over-the-counter health brands, linking its performance to US consumer confidence, healthcare spending and demographic trends, according to geographical breakdowns in the 2024 annual report, as noted in Reckitt annual report 2024 as of 03/15/2025.

US investors interested in defensive or consumer-staples-style exposure may monitor Reckitt as part of a broader peer group that includes global packaged goods and healthcare companies. The stock’s performance can provide insight into trends such as demand for disinfectants, cold and flu remedies and infant nutrition, which can have read-across effects to listed US peers. In addition, legal developments in US courts related to the company’s infant formula business are closely watched by market participants because they may influence not only Reckitt’s financial risk profile but also the regulatory environment for the wider sector, as observed by analysts quoted in Reuters as of 03/01/2025.

From a portfolio construction perspective, some US investors gain exposure to Reckitt through global or international equity funds and ETFs that hold UK-listed consumer companies. For these investors, understanding the company’s strategic priorities, legal risks and currency exposure helps contextualize how Reckitt might contribute to overall portfolio risk and return. Movements in the British pound against the US dollar can also influence the translated value of Reckitt’s earnings and dividends for dollar-based investors, adding another factor to consider when following the stock.

Conclusion

Reckitt Benckiser Group is navigating a complex mix of slower sales growth, operational turnaround efforts and legal uncertainties, particularly in its US infant nutrition business. At the same time, the company retains a portfolio of well-known brands in health and hygiene categories that benefit from structural demand trends and recurring consumer usage. For investors, the key questions revolve around how effectively management can stabilize growth, protect margins and address legal risks while continuing to invest in brand equity and innovation. The stock’s performance will likely remain closely tied to execution on these priorities and to broader consumer and regulatory developments in its major markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.